23 June 2022  
EMA/604944/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Nuvaxovid 
SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from 
Spodoptera frugiperda 
On 23 June 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Nuvaxovid. The marketing authorisation holder for this medicinal product is Novavax CZ, a.s. 
The CHMP adopted an extension to the existing indication as follows:2 
Nuvaxovid is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in 
individuals 18 12 years of age and older. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us 
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union  
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
